.

Radium-223 for the treatment of castration-resistant prostate cancer

LAUR Repository

Show simple item record

dc.contributor.author El-Amm, Joelle
dc.contributor.author Aragon-Ching, Jeanny B.
dc.date.accessioned 2017-09-25T08:06:16Z
dc.date.available 2017-09-25T08:06:16Z
dc.date.copyright 2015 en_US
dc.identifier.issn 1178-6930 en_US
dc.identifier.uri http://hdl.handle.net/10725/6261
dc.description.abstract The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. Bone metastases are a source of significant morbidity and affect quality of life in these patients. Several bone-targeting agents are approved for the treatment of bone metastases in prostate cancer, including bisphosphonates, denosumab, and radiopharmaceuticals. Radium-223 is a novel first-in-class alpha-emitting radiopharmaceutical that has been approved for treatment of patients with mCRPC with bone metastases. Radium-223 delivers cytotoxic radiation to the sites of bone metastases and offers the advantage of minimal myelosuppression. The landmark Phase III ALSYMPCA trial demonstrated that, in addition to providing bone-related palliation, radium-223 can also prolong overall survival in patients with mCRPC with bone metastases in the absence of visceral metastases and in the absence of lymphadenopathy greater than 3 cm. Ongoing trials will further elucidate its use in sequence or combination with other available therapies for mCRPC. en_US
dc.language.iso en en_US
dc.title Radium-223 for the treatment of castration-resistant prostate cancer en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201603787 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal OncoTargets and Therapy en_US
dc.journal.volume 8 en_US
dc.article.pages 1103-1109 en_US
dc.keywords Prostate cancer en_US
dc.keywords Radiopharmaceuticals en_US
dc.keywords Bone metastases en_US
dc.keywords Radium-223 en_US
dc.identifier.doi http://dx.doi.org/10.2147/OTT.S44291 en_US
dc.identifier.ctation El-Amm, J., & Aragon-Ching, J. B. (2015). Radium-223 for the treatment of castration-resistant prostate cancer. OncoTargets and therapy, 8, 1103. en_US
dc.author.email joelle.elamm@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445785/ en_US
dc.author.affiliation Lebanese American University en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR


Advanced Search

Browse

My Account